Curasight A/S
Andreas Kjaer is a distinguished academic and medical professional, currently serving as a Professor and Chief Physician at Rigshospitalet and the University of Copenhagen since 2003. Kjaer heads the Cluster for Molecular Imaging and is a co-founder of Minerva Imaging and Curasight, as well as the founder of FluoGuide A/S. Kjaer holds key editorial roles, including International Associate Editor for the Journal of Nuclear Medicine and Founding Editor-in-chief for Diagnostics MDPI. In addition, Kjaer has been involved with various organizations such as the Lundbeck Foundation Danish-American Research Exchange Program and the Danish Academy of Technical Sciences. Kjaer's extensive education includes an MD, PhD, and DMSc from the University of Copenhagen, an MBA from Copenhagen Business School, advanced programs at Harvard Business School and INSEAD, and a background in mathematics and physics.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.